Growth Investors: Industry Analysts Just Upgraded Their Berry Corporation (NASDAQ:BRY) Revenue Forecasts By 13%

Celebrations may be in order for Berry Corporation (NASDAQ:BRY) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have sharply increased their revenue numbers, with a view that Berry will make substantially more sales than they'd previously expected.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following the upgrade, the most recent consensus for Berry from its two analysts is for revenues of US$748m in 2025 which, if met, would be a modest 6.6% increase on its sales over the past 12 months. Before the latest update, the analysts were foreseeing US$664m of revenue in 2025. The consensus has definitely become more optimistic, showing a nice increase in revenue forecasts.

Check out our latest analysis for Berry

There was no particular change to the consensus price target of US$4.40, with Berry's latest outlook seemingly not enough to result in a change of valuation.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Berry's past performance and to peers in the same industry. The analysts are definitely expecting Berry's growth to accelerate, with the forecast 14% annualised growth to the end of 2025 ranking favourably alongside historical growth of 9.9% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 3.9% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Berry is expected to grow much faster than its industry.

The Bottom Line

The highlight for us was that analysts increased their revenue forecasts for Berry this year. The analysts also expect revenues to grow faster than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Berry.

Want to learn more? We have analyst estimates for Berry going out to 2027, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.